miR-138-5p在非小细胞肺癌中的表达及临床意义
|
摘要
目的探讨微小RNA-138-5p(miR-138-5p)在非小细胞肺癌(NSCLC)中的表达及临床意义。方法采用实时荧光定量PCR(QPCR)检测102例NSCLC组织和98例癌旁组织中miRNA-138-5p表达,分析miRNA-138-5p表达与NSCLC临床病理特征(性别、年龄、TNM分期、肿瘤直径和淋巴结转移)的关系; Kaplan-Miere法绘制生存曲线,差异行Log-rank检验;Cox回归模型分析影响总生存(OS)的因素。结果 QPCR检测结果显示,NSCLC组织中miR-138-5p表达水平为0. 42±0. 11,显著低于癌旁组织的1. 03±0. 28,差异具有统计学意义(P<0. 05)。miR-138-5p表达与TNM分期、肿瘤直径及淋巴结转移均有关(P<0. 05)。miR-138-5p高表达者的中位OS>36个月,显著高于低表达者的26个月,差异有统计学意义(P<0. 05)。Cox单因素分析显示除miR-138-5p表达外,淋巴结转移、肿瘤直径和TNM分期也与OS有关(P<0. 05)。结论 miR-138-5p在NSCLC中表达下调,其表达与NSCLC发生发展、预后有关,miR-138-5p可作为NSCLC诊断和预后预测新的靶点。
Objective To investigate the expression and significance of miRNA-138-5p( miR-138-5p) in non-small cell lung cancer( NSCLC). Methods Real-time fluorescence quantitative PCR( QPCR) was used to detect the expression of miR-138-5p in102 NSCLC tissues and 98 paracancerous tissues. The relationship between the expression of miR-138-5p and the clinicopathological features of NSCLC( sex,age,TNM stage,tumor size and lymph node metastasis) were analyzed. The survival curve was drawn by Kaplan-Miere method,and the difference was checked by Log-rank test. Cox regression model was used to analyze the factors affecting overall survival( OS). Results The expression level of miR-138-5p in NSCLC tissues was 0. 42±0. 11,significantly lower than 1. 03 ±0. 28 in adjacent tissues( P<0. 05). The expression of miR-138-5p was correlated with TNM stage,tumor size and lymph node metastasis( P<0. 05). The median OS of high expression of miR-138-5p was more than 36 months,which was significantly higher than that of low expression of miR-138-5p( P< 0. 05). Cox univariate analysis showed that besides the expression of miR-138-5p,lymph node metastasis,tumor size and TNM stage were also associated with OS( P<0. 05). Conclusion The expression of miR-138-5p is downregulated in NSCLC,which is related to the development and prognosis of NSCLC. MiR-138-5p can be used as a new target for diagnosis and prognosis prediction of NSCLC.
Objective To investigate the expression and significance of miRNA-138-5p( miR-138-5p) in non-small cell lung cancer( NSCLC). Methods Real-time fluorescence quantitative PCR( QPCR) was used to detect the expression of miR-138-5p in102 NSCLC tissues and 98 paracancerous tissues. The relationship between the expression of miR-138-5p and the clinicopathological features of NSCLC( sex,age,TNM stage,tumor size and lymph node metastasis) were analyzed. The survival curve was drawn by Kaplan-Miere method,and the difference was checked by Log-rank test. Cox regression model was used to analyze the factors affecting overall survival( OS). Results The expression level of miR-138-5p in NSCLC tissues was 0. 42±0. 11,significantly lower than 1. 03 ±0. 28 in adjacent tissues( P<0. 05). The expression of miR-138-5p was correlated with TNM stage,tumor size and lymph node metastasis( P<0. 05). The median OS of high expression of miR-138-5p was more than 36 months,which was significantly higher than that of low expression of miR-138-5p( P< 0. 05). Cox univariate analysis showed that besides the expression of miR-138-5p,lymph node metastasis,tumor size and TNM stage were also associated with OS( P<0. 05). Conclusion The expression of miR-138-5p is downregulated in NSCLC,which is related to the development and prognosis of NSCLC. MiR-138-5p can be used as a new target for diagnosis and prognosis prediction of NSCLC.
引文
[1]林潇,陈愉生,李鸿茹,等.非小细胞肺癌淋巴结转移与临床病理特征及预后的相关性分析[J].临床肿瘤学杂志,2015,20(12):1110-1116.
[2] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3]许德兵,宋勇.分子生物标志物在肺癌早期诊断中的研究进展[J].医学研究生学报,2013,26(7):766-770.
[4] Miller KD,Siegel RL,Lin CC,et al. Cancer treatment and survivorship statistics,2016[J]. CA Cancer J Clin,2016,66(4):271-289.
[5] Nanavaty P,Alvarez MS,Alberts WM. Lung cancer screening:advantages,controversies,and applications[J]. Cancer Control,2014,21(1):9-14.
[6] Zhang Y,Yang Q,Wang S. MicroRNAs:a new key in lung cancer[J]. Cancer Chemother Pharmacol, 2014, 74(6):1105-1111.
[7] Tutar L,Tutar E,zgür A,et al. Therapeutic targeting of microRNAs in cancer:future perspectives[J].Drug Dev Res,2015,76(7):382-388.
[8]王杰,喻超,周显飞,等.MiRNA-138-5p抑制人胰腺癌细胞增殖能力[J].世界华人消化杂志,2016,24(28):3970-3977.
[9]杨伟,张娜,金丽娟,等.胃癌细胞株BGC-823中miR-138-5p负性调控Sirt1基因的表达[J].宁夏医科大学学报,2016,38(9):980-984,993,1102.
[10]韩真真,衣晓丽,袁胜利,等.阿帕替尼治疗肺癌的研究进展[J].临床肿瘤学杂志,2018,23(2):185-188.
[11]王晓红,马建群,白淑平.NI和NP方案对复发性非小细胞肺癌的临床疗效[J].临床肿瘤学杂志,2003,8(5):368-369.
[12] Kim HS,Lee KS,Bae HJ,et al. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer[J]. Oncotarget,2015,6(10):8089-8102.
[13] Ayers D,Vandesompele J. Influence of microRNAs and long noncoding RNAs in cancer chemoresistance[J]. Genes(Basel),2017[2018-07-11]. https://www. ncbi. nlm. nih. gov/pubmed/28273813.
[14]王启船,王青,万里新,等.微小RNA-204在非小细胞肺癌中的表达及对H252癌细胞增殖及凋亡的影响[J].中国实验诊断学,2018,22(6):1009-1012.
[15]律方,薛奇.miR-614通过调控靶基因PSA表达抑制人肺癌细胞的侵袭和增殖能力[J].中国肺癌杂志,2014,17(10):715-721.
[16]赵玉明,李艳星,朱晓锋,等.MiR-21对肺癌细胞增殖与凋亡的影响[J].中国老年学杂志,2017,37(8):1869-1871.
[17] Liu Y,Zhang W,Liu K,et al. miR-138 suppresses cell proliferation and invasion by inhibiting SOX9 in hepatocellular carcinoma[J].Am J Transl Res,2016,8(5):2159-2168.
[18]吕俊杰,徐磊,许有涛,等.非小细胞肺癌组织miRNA-221表达及其与预后的关系研究[J].中国肺癌杂志,2014,17(3):221-225.
[19]张伟,张潍,刘伟良,等.非小细胞肺癌中miRNA-141的表达及临床意义[J].现代肿瘤医学,2015,23(3):329-332.
[2] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3]许德兵,宋勇.分子生物标志物在肺癌早期诊断中的研究进展[J].医学研究生学报,2013,26(7):766-770.
[4] Miller KD,Siegel RL,Lin CC,et al. Cancer treatment and survivorship statistics,2016[J]. CA Cancer J Clin,2016,66(4):271-289.
[5] Nanavaty P,Alvarez MS,Alberts WM. Lung cancer screening:advantages,controversies,and applications[J]. Cancer Control,2014,21(1):9-14.
[6] Zhang Y,Yang Q,Wang S. MicroRNAs:a new key in lung cancer[J]. Cancer Chemother Pharmacol, 2014, 74(6):1105-1111.
[7] Tutar L,Tutar E,zgür A,et al. Therapeutic targeting of microRNAs in cancer:future perspectives[J].Drug Dev Res,2015,76(7):382-388.
[8]王杰,喻超,周显飞,等.MiRNA-138-5p抑制人胰腺癌细胞增殖能力[J].世界华人消化杂志,2016,24(28):3970-3977.
[9]杨伟,张娜,金丽娟,等.胃癌细胞株BGC-823中miR-138-5p负性调控Sirt1基因的表达[J].宁夏医科大学学报,2016,38(9):980-984,993,1102.
[10]韩真真,衣晓丽,袁胜利,等.阿帕替尼治疗肺癌的研究进展[J].临床肿瘤学杂志,2018,23(2):185-188.
[11]王晓红,马建群,白淑平.NI和NP方案对复发性非小细胞肺癌的临床疗效[J].临床肿瘤学杂志,2003,8(5):368-369.
[12] Kim HS,Lee KS,Bae HJ,et al. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer[J]. Oncotarget,2015,6(10):8089-8102.
[13] Ayers D,Vandesompele J. Influence of microRNAs and long noncoding RNAs in cancer chemoresistance[J]. Genes(Basel),2017[2018-07-11]. https://www. ncbi. nlm. nih. gov/pubmed/28273813.
[14]王启船,王青,万里新,等.微小RNA-204在非小细胞肺癌中的表达及对H252癌细胞增殖及凋亡的影响[J].中国实验诊断学,2018,22(6):1009-1012.
[15]律方,薛奇.miR-614通过调控靶基因PSA表达抑制人肺癌细胞的侵袭和增殖能力[J].中国肺癌杂志,2014,17(10):715-721.
[16]赵玉明,李艳星,朱晓锋,等.MiR-21对肺癌细胞增殖与凋亡的影响[J].中国老年学杂志,2017,37(8):1869-1871.
[17] Liu Y,Zhang W,Liu K,et al. miR-138 suppresses cell proliferation and invasion by inhibiting SOX9 in hepatocellular carcinoma[J].Am J Transl Res,2016,8(5):2159-2168.
[18]吕俊杰,徐磊,许有涛,等.非小细胞肺癌组织miRNA-221表达及其与预后的关系研究[J].中国肺癌杂志,2014,17(3):221-225.
[19]张伟,张潍,刘伟良,等.非小细胞肺癌中miRNA-141的表达及临床意义[J].现代肿瘤医学,2015,23(3):329-332.